Ensysce Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on July 15, 2026, covering events occurring on July 10, 2026. The Company is a Delaware corporation with its principal executive offices in La Jolla, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "ENSC."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
On July 10, 2026, Jeffrey Millard submitted a resignation notice effective immediately. Mr. Millard served as the Company's Chief Operating Officer. This departure is the primary material event reported in this filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for updated guidance, outlook, management commentary on future strategy, specific risks, or contingencies related to the resignation. No unusual items were disclosed in this report.
Key Facts for Investor Verification
- Jeffrey Millard resigned as Chief Operating Officer effective July 10, 2026.
- The resignation was reported to the SEC on July 15, 2026.
- Dr. Lynn Kirkpatrick, President and Chief Executive Officer, signed the report.
- Investors should verify if a replacement for the Chief Operating Officer has been appointed or if an interim leader has been named.